Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen
Open Access
- 1 May 2013
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 190 (9) , 4887-4898
Abstract
Ag activation of the BCR may play a role in the pathogenesis of human follicular lymphoma (FL) and other B cell malignancies. However, the nature of the Ag(s) recognized by tumor BCRs has not been well studied. In this study, we used unbiased approaches to demonstrate that 42 (19.35%) of 217 tested FL Igs recognized vimentin as a shared autoantigen. The epitope was localized to the N-terminal region of vimentin for all vimentin-reactive tumor Igs. We confirmed specific binding to vimentin by using recombinant vimentin and by performing competitive inhibition studies. Furthermore, using indirect immunofluorescence staining, we showed that the vimentin-reactive tumor Igs colocalized with an anti-vimentin mAb in HEp-2 cells. The reactivity to N-terminal vimentin of IgG FL Igs was significantly higher than that of IgM FL Igs (30.4 versus 10%; p = 0.0022). However, vimentin-reactive FL Igs did not share CDR3 motifs and were not homologous. Vimentin was expressed in the T cell–rich regions of FL, suggesting that vimentin is available for binding with tumor BCRs within the tumor microenvironment. Vimentin was also frequently recognized by mantle cell lymphoma and multiple myeloma Igs. Our results demonstrate that vimentin is a shared autoantigen recognized by nonstereotyped FL BCRs and by the Igs of mantle cell lymphoma and multiple myeloma and suggest that vimentin may play a role in the pathogenesis of multiple B cell malignancies. These findings may lead to a better understanding of the biology and natural history of FL and other B cell malignancies.Keywords
This publication has 52 references indexed in Scilit:
- B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progressionProceedings of the National Academy of Sciences, 2010
- Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular LymphomaJournal of Clinical Oncology, 2009
- Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIABlood, 2008
- Dual roles of intermediate filaments in apoptosisExperimental Cell Research, 2007
- Autoreactivity in Human IgG+ Memory B CellsImmunity, 2007
- Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cellsBlood, 2006
- Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesisJournal of Experimental Medicine, 2006
- Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma AntigenClinical Cancer Research, 2004
- Expressed Murine and Human CDR-H3 Intervals of Equal Length Exhibit Distinct Repertoires that Differ in their Amino Acid Composition and Predicted Range of StructuresJournal of Molecular Biology, 2003
- A simple method for displaying the hydropathic character of a proteinJournal of Molecular Biology, 1982